StreetInsider.com News Articles

Form 8-K Kiromic Biopharma, Inc. For: Mar 21

Fri, 21 Mar 2025 09:05:00 -0400

si-local-file:///var/storage/secattach/20250321/24532085.html

Form 8-K Kiromic Biopharma, Inc. For: Mar 21

Fri, 21 Mar 2025 09:05:00 -0400

si-local-file:///var/storage/secattach/20250321/24532085.html

Form 8-K Kiromic Biopharma, Inc. For: Mar 11

Mon, 17 Mar 2025 17:27:00 -0400

si-local-file:///var/storage/secattach/20250317/24511279.html

Form 8-K Kiromic Biopharma, Inc. For: Mar 11

Mon, 17 Mar 2025 17:27:00 -0400

si-local-file:///var/storage/secattach/20250317/24511279.html

Form S-1/A Kiromic Biopharma, Inc.

Wed, 19 Feb 2025 16:58:00 -0400

si-local-file:///var/storage/secattach/20250219/24372749.html

Form S-1/A Kiromic Biopharma, Inc.

Wed, 19 Feb 2025 16:58:00 -0400

si-local-file:///var/storage/secattach/20250219/24372749.html

Kiromic BioPharma Reports Patient 4 in Deltacel-01 Clinical Trial Reaches 10-Month Progression-Free Survival

Tue, 18 Feb 2025 08:00:00 -0400

HOUSTON--(BUSINESS WIRE)-- Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) reports continued favorable efficacy results from the 10-month follow-up visit for the fourth patient enrolled in its Deltacel-01 Phase 1 clinical trial and provides an enrollment update. This trial is evaluating Deltacel™ (KB-GDT-01), the Company’s allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy, in patients with stage 4 metastatic or locally-advanced non-small cell lung cancer (NSCLC) who have failed to respond to standard therapies.

The fourth patient in Deltacel-01 demonstrated a partial response (defined as a 30% or greater decrease in the size of the tumor) at the

Kiromic BioPharma Reports Patient 4 in Deltacel-01 Clinical Trial Reaches 10-Month Progression-Free Survival

Tue, 18 Feb 2025 08:00:00 -0400

The fourth patient in Deltacel-01 demonstrated a partial response (defined as a 30% or greater decrease in the size of the tumor) at the

Kiromic BioPharma Reports Patient 4 in Deltacel-01 Clinical Trial Reaches 10-Month Progression-Free Survival

Tue, 18 Feb 2025 08:00:00 -0400

The fourth patient in Deltacel-01 demonstrated a partial response (defined as a 30% or greater decrease in the size of the tumor) at the

Kiromic BioPharma Reports Patient 4 in Deltacel-01 Clinical Trial Reaches 10-Month Progression-Free Survival

Tue, 18 Feb 2025 08:00:00 -0400

The fourth patient in Deltacel-01 demonstrated a partial response (defined as a 30% or greater decrease in the size of the tumor) at the

Form 10-K Kiromic Biopharma, Inc. For: Dec 31

Fri, 14 Feb 2025 16:15:00 -0400

si-local-file:///var/storage/secattach/20250214/24354705.html

Form 10-K Kiromic Biopharma, Inc. For: Dec 31

Fri, 14 Feb 2025 16:15:00 -0400

si-local-file:///var/storage/secattach/20250214/24354705.html

Form 8-K/A Kiromic Biopharma, Inc. For: Jan 28

Mon, 03 Feb 2025 16:11:00 -0400

si-local-file:///var/storage/secattach/20250203/24286836.html

Form 8-K/A Kiromic Biopharma, Inc. For: Jan 28

Mon, 03 Feb 2025 16:11:00 -0400

si-local-file:///var/storage/secattach/20250203/24286836.html

Form 8-K Kiromic Biopharma, Inc. For: Jan 28

Mon, 03 Feb 2025 11:10:00 -0400

si-local-file:///var/storage/secattach/20250203/24285016.html

Form 8-K Kiromic Biopharma, Inc. For: Jan 28

Mon, 03 Feb 2025 11:10:00 -0400

si-local-file:///var/storage/secattach/20250203/24285016.html

Kiromic BioPharma Reports Tumor Volume Decrease in Two Patients Enrolled in Deltacel-01

Tue, 21 Jan 2025 08:00:00 -0400